Effect of bortezomib combined with dexamethasone on biochemical indexes in patients with multiple myeloma bone disease
- VernacularTitle:硼替佐米结合地塞米松对多发性骨髓瘤骨病患者生化指标的影响
- Author:
Zenghuai LI
- Publication Type:Journal Article
- Keywords:
bortezomib;
dexamethasone;
multiple myeloma;
biochemical index
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;37(4):138-140,143
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect and biochemical index changes of bortezomib combined with dexamethasone in multiple myeloma bone disease.Methods A total of 40 cases of multiple myeloma patients were randomly divided into experimental group (20 cases) and control group (20 cases), two groups of patients were treated with zoledronic acid, the experiment group adopted the bortezomib and dexamethasone treatment scheme, control group received dexamethasone+vincristine+epirubicin scheme.After 3 courses of treatment,compared the pain relieving degree,clinical efficacy and adverse reactions incidence, and analysed serum calcium, phosphorus, DDK1, RANKL, TRACP-5b and ALP levels of two groups.Results After the end of chemotherapy,bone pain in two groups was significantly relieved,and the pain relieving degree experimental group was significantly better than the control group (P<0.05).Total effective rate in experimental group was 95.0%, significantly higher than that in control group 65.0%(χ2 =5.625,P=0.018).The adverse reaction rate had no significant difference between two groups.The of calcium, phosphorus after chemotherapy, DDK1, RANKL, TRACP-5b levels in experimental group were significantly lower than those in control group, ALP was significantly higher than that of control group (P<0.05).Conclusion Bortezomib in combination with dexamethasone can significantly improve the curative effect of multiple myeloma,and its mechanism may regulate DDK1, RANKL, TRACP-5b levels,and balance the osteolytic and osteoblastic process.
